Kaijing Wang1, Qixin Jiang2, Yunqing Zhi3, Zhe Zhu2, Zhuqing Zhou2, Yanting Xie2, Xiaoqi Yin2, Aiguo Lu2. 1. 1 Department of Gastroenterological Surgery, Shanghai Tongji Hospital, Tongji University School of Medicine , Shanghai, China . 2. 2 Department of Gastroenterological Surgery, Shanghai East Hospital, Tongji University School of Medicine , Shanghai, China . 3. 3 Department of Obstetrics and Gynecology, The Affiliated Hospital of Medical College, Qingdao University , Qingdao, China .
Abstract
AIMS: To explore the feasibility of sleeve gastrectomy (SG) as a treatment for polycystic ovary syndrome (PCOS) and its potential to improve clinical efficacy in PCOS patients with symptoms of oligomenorrhea. PATIENTS AND METHODS: Twenty-four obese patients with PCOS underwent laparoscopic SG. Simultaneously, 24 obese patients with PCOS received lifestyle modification therapy (LMT). Follow-ups were conducted at 3-6 months. Weight loss, menstruation, and improvements in hirsutism and metabolic symptoms were compared. RESULTS: In the SG group, 20 patients were restored to normal menstrual cycles and ovulation at 3-6 months after surgery. Their average androgen levels decreased significantly following surgery (P=.012). Conversely, only 6 patients in the LMT group were restored to normal menstrual cycles and ovulation after receiving 3 months of treatment. Their average preoperative and postoperative androgen levels showed a nonstatistically significant decrease (P>.05). Compared with the LMT group, the SG group showed more pronounced improvements in menstruation. Additionally, body mass and body mass index were significantly reduced in patients in the SG group 3 months after the surgeries, with maximum weight loss observed at approximately 6 months after surgery. Patients who received LMT showed a gradual weight reduction such that body mass decreased significantly after 3 months (P<. 001). Compared with patients in the LMT group, patients in the SG group showed greater weight loss results (P<.0001). CONCLUSIONS: In patients with PCOS, SG resulted in more marked weight loss and better improvements in clinical symptoms compared with LMT.
AIMS: To explore the feasibility of sleeve gastrectomy (SG) as a treatment for polycystic ovary syndrome (PCOS) and its potential to improve clinical efficacy in PCOSpatients with symptoms of oligomenorrhea. PATIENTS AND METHODS: Twenty-four obesepatients with PCOS underwent laparoscopic SG. Simultaneously, 24 obesepatients with PCOS received lifestyle modification therapy (LMT). Follow-ups were conducted at 3-6 months. Weight loss, menstruation, and improvements in hirsutism and metabolic symptoms were compared. RESULTS: In the SG group, 20 patients were restored to normal menstrual cycles and ovulation at 3-6 months after surgery. Their average androgen levels decreased significantly following surgery (P=.012). Conversely, only 6 patients in the LMT group were restored to normal menstrual cycles and ovulation after receiving 3 months of treatment. Their average preoperative and postoperative androgen levels showed a nonstatistically significant decrease (P>.05). Compared with the LMT group, the SG group showed more pronounced improvements in menstruation. Additionally, body mass and body mass index were significantly reduced in patients in the SG group 3 months after the surgeries, with maximum weight loss observed at approximately 6 months after surgery. Patients who received LMT showed a gradual weight reduction such that body mass decreased significantly after 3 months (P<. 001). Compared with patients in the LMT group, patients in the SG group showed greater weight loss results (P<.0001). CONCLUSIONS: In patients with PCOS, SG resulted in more marked weight loss and better improvements in clinical symptoms compared with LMT.
Authors: Joshua Dilday; Michael Derickson; John Kuckelman; Cara Reitz; Eric Ahnfeldt; Matthew Martin; J Paul Sanders Journal: Obes Surg Date: 2019-01 Impact factor: 4.129
Authors: Arshiya Mariam; Galen Miller-Atkins; Kevin M Pantalone; Neeraj Iyer; Anita D Misra-Hebert; Alex Milinovich; Janine Bauman; Michelle Mocarski; Abhilasha Ramasamy; B Gabriel Smolarz; Todd M Hobbs; Robert S Zimmerman; Bartolome Burguera; Michael W Kattan; Daniel M Rotroff Journal: Diabetes Obes Metab Date: 2021-09-28 Impact factor: 6.408